Resources

iPSC-derived hepatocytes accurately recapitulate population diversity in alpha-1-antitrypsin deficiency and offer a novel in vitro model for large-scale drug efficacy screening studies

Background Alpha-1 antitrypsin deficiency (A1ATD) is a...

Ornithine transcarbamylase (OTC)

DefiniGEN human iPSC-derived Ornithine transcarbamylase...

Wilson's disease

DefiniGEN human iPSC-derived Wilson’s disease modelled...

Alpha-1 antitrypsin deficiency

DefiniGEN human iPSC-derived Alpha-1 Antitrypsin...

Hepatocyte cell functionality

DefiniGEN’s proprietary differentiation protocol...

Discover DefiniGEN

Download a short introduction to DefiniGEN, learn more...

Development of optimised human iPSC-derived hepatocytes with improved liver function for in vitro metabolic disease modelling and toxicity studies

Abstract Background & Aims Liver disease is a rising...

Modeling Disease with Human Inducible Pluripotent Stem Cells

Understanding the physiopathology of disease remains an...

Production of hepatocyte-like cells from human pluripotent stem cells

Large-scale production of hepatocytes from a variety of...

Generation of Hepatocytes from Pluripotent Stem Cells for Drug Screening and Developmental Modeling

Hepatocytes produced from the differentiation of human...

Discover how iPSC derived cells can be used to support the development of drug and gene therapies

A considerable roadblock in the successful triaging of...

Using iPSC-Derived Hepatocyte Models for Disease Modeling and Predictive Toxicology Screening

In this GEN webinar, our speakers will present new...

Opti-HEP Functionality

DefiniGEN’s proprietary differentiation protocols...

Generation of multipotent foregut stem cells from human pluripotent stem cells

Human pluripotent stem cells (hPSCs) could provide an...

Developing iPSC-Derived Liver Systems for MASLD Modeling and Therapy Screening

Alpha-1 Antitrypsin Deficiency

Learn more about how our CRISPR-derived A1AT cells can...